Extended Infant RSV Administration Season
This message is being sent to VFC providers, local health officers, Tribal health directors, local health nurses, local health department staff, and select DHS employees.
sThe Wisconsin Department of Health Services (DHS) recommends that clinicians continue administering RSV monoclonal antibody products to eligible infants until April 30, 2026. Read the memo Recommendation To Continue Administration Of Respiratory Syncytial Virus (RSV) Monoclonal Antibody Products Beyond March 31, 2026.
Current Wisconsin surveillance data indicate that RSV transmission remains ongoing and has not yet declined to typical interseasonal levels. Continuing RSV prevention beyond the usual end-date of March 31 will help protect infants born late in the respiratory virus season while RSV continues to circulate in Wisconsin communities.
What does this mean for providers?
- Continue to immunize infants with RSV products, nirsevimab (Beyfortus) or clesrovimab (Enflonsia), through April 30, 2026.
- Ordering of these two products through VFC will still be available through the month of April. Product will have an expiration date of August or September of 2026. This product will expire before the start of next infant RSV administration season; plan accordingly when ordering additional stock.
If your RSV product expires, it must be returned using the vaccine return request form as you would any other expired VFC vaccines.
Reminder: It is not too late to administer 2025–26 flu and COVID vaccines. These vaccines can be given up until the expiration date.
|
